Liquidia
LQDA | NASDAQ
$56.37
-$1.04 (-1.81%)
At close: Nov 16, 2026, 4:00 PM ET
$56.30
-$0.07 (-0.12%)
After-hours:
Nov 16, 2026, 7:47 PM ET
Liquidia Company Profile
Company profile explainedCompany Profile
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Key Executives
| Name | Position |
|---|---|
| Roger A. Jeffs | Chief Executive Officer & Director |
| Michael Kaseta | Chief Operating Officer & Chief Financial Officer |
| Christian Perez Font | Senior Vice President, Chief Compliance Officer & Associate General Counsel |
| Dana Boyle | Chief Accounting Officer |
| Jason Adair | Chief Business Officer |
| Matt Snow | Senior Vice President of Sales |
| Michael Post | Senior Vice President of Marketing |
| Rajeev Saggar | Chief Medical Officer |
| Russell Schundler | General Counsel & Corporate Secretary |
| Sarah Krepp SPHR | Chief Human Resources Officer |
| Scott Moomaw | Chief Commercial Officer |
Liquidia
| Country | United States |
| IPO Date | Jul 26, 2018 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 216 |
| CEO | Roger A. Jeffs |
Contact Details
419 Davis Drive Morrisville,
North Carolina 27560 United States
Stock Details
| Ticker Symbol | LQDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819576 |
| CUSIP Number | 53635D202 |
| ISIN Number | US53635D2027 |
| SIC Code | 2834 |
Recent News
- 2 days ago / seekingalpha.comLiquidia: Yutrepia's PAH Franchise Has Room To Grow
- 5 days ago / zacks.comLQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
- 5 days ago / zacks.comLQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
- 6 days ago / marketbeat.comLiquidia Q3 Earnings Call Highlights
- 6 days ago / seekingalpha.comLiquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
- 6 days ago / zacks.comLiquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
- 6 days ago / globenewswire.comLiquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
- 6 days ago / globenewswire.comLiquidia Corporation Reports Third Quarter 2026 Financial Results
- 14 days ago / globenewswire.comLiquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
- 20 days ago / zacks.comLiquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
Add to Watchlist
Select watchlists to add or remove LQDA